Search clinical trials for: Growth Hormone Therapy

Total 105988 results

Isfahan University of Medical Sciences

Recruiting

Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compared to Placebo in Patients With Thin Endometrium Undergoing Frozen Thawed Embryo Transfer

Infertility | Thin Endometrium | Infertility Female

Iran, Islamic Republic of
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
University of Chicago

Not yet recruiting

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
Lebanese University
Haykel Hospital

Recruiting

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA (PTST_PALBEVA)

Cancer | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Chemotherapy | Solid Tumor | Immunotherapy | Targeted Therapy | Precision Therapy

Lebanon
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
Istituto Auxologico Italiano

Recruiting

Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy (ETABIOGHD)

Growth Hormone Deficiency | Short Stature

Italy
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Mridula George, MD

Recruiting

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Breast Cancer

United States
Medical College of Wisconsin

Not yet recruiting

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Breast Cancer

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

United States, Israel, Taiwan, Argentina, Japan, Korea, Republic of, Canada, Australia, Brazil
M.D. Anderson Cancer Center

Recruiting

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Ovarian Cancer

United States
Mayo Clinic

Recruiting

Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
4D Molecular Therapeutics

Recruiting

4D-150 in Patients With Diabetic Macular Edema

Diabetic Retinopathy | Diabetic Macular Edema

United States, Puerto Rico
Ruijin Hospital

Recruiting

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Follicular Lymphoma

China
Novartis Pharmaceuticals

Recruiting

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA)

Follicular Lymphoma (FL)

Australia, Korea, Republic of, Spain, Singapore, Poland, Taiwan, Hungary, Romania, Slovakia
Novartis Pharmaceuticals

Recruiting

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Breast Cancer

France, Spain, Portugal
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer

Taiwan, Korea, Republic of, Greece, Spain, United States, Israel, France, Japan, Belgium, Poland, China, Singapore, Australia, Hungary, Czechia, Italy, South Africa, Hong Kong, Chile, Brazil, Argentina, Austria, Canada, Germany, Portugal, United Kingdom
University of Heidelberg Medical Center
Sanofi; KKS Netzwerk; Deutsche Studiengruppe Multiples Myelom (DSMM)

Recruiting

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Germany, Austria
Affiliated Hospital of Nantong University

Recruiting

The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients

Multiple Myeloma

China
Ascendis Pharma Endocrinology Division A/S

Recruiting

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin (SkyPASS)

Growth Hormone Deficiency

United States
Universitätsklinikum Hamburg-Eppendorf
Gemeinsamer Bundesausschuss (G-BA); Staburo GmbH

Recruiting

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)

Multiple Myeloma

Germany
University Hopsital Schleswig Holstein Campus Lübeck

Recruiting

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients (ELIAS)

Newly Diagnosed Multiple Myeloma

Germany
University of Calgary
Pfizer

Not yet recruiting

Growth Hormone Deficiency in Mild Traumatic Brain Injury

Growth Hormone Deficiency | Growth Hormone Treatment | Concussion Post Syndrome | Concussion, Mild
Fujian Cancer Hospital

Not yet recruiting

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Rectal Cancer
Atossa Therapeutics, Inc.
InClin

Recruiting

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE)

Breast Neoplasms | Invasive Breast Cancer | HER2-negative Breast Cancer | Estrogen-receptor-positive Breast Cancer

United States
Hellenic Society of Hematology
GlaxoSmithKline

Not yet recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Neoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Multiple Myeloma in Relapse | Gammopathy, Monoclonal | Haematologic Disease
Seung-Whan Lee, M.D., Ph.D.
Yuhan Corporation

Recruiting

Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)

Pre Diabetes | ASCVD

Korea, Republic of
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
The Affiliated Hospital of Qingdao University

Not yet recruiting

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

DLBCL

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

First-line Olaparib Combined With Bevacizumab Maintenance Therapy

Ovarian Neoplasms
Kite, A Gilead Company

Recruiting

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22)

Relapsed/Refractory Follicular Lymphoma

United States, Spain, United Kingdom, Italy, France, Japan, Germany
Baylor College of Medicine
United States Department of Defense

Recruiting

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) (GWIT)

Gulf War Syndrome | Adult Growth Hormone Deficiency

United States
Hellenic Society of Hematology
Sanofi

Not yet recruiting

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Renal Impairment

Greece
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
Stichting European Myeloma Network
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Multiple Myeloma

Netherlands, Spain, United States, Belgium, France, Italy, Germany, Japan, Canada, Australia, Sweden, Israel, United Kingdom, Czechia, Greece, Switzerland, Norway
University of Alabama at Birmingham
Janssen Scientific Affairs, LLC

Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Multiple Myeloma

United States
Tongji Hospital
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants

Growth Hormone Treatment | Small for Gestational Age Infant | Cognitive Developmental Disorder

China
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Sanofi

Recruiting

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy (IsAMYP)

AL Amyloidosis

France
Tongji Hospital
Sun Yat-sen University; First Affiliated Hospital, Sun Yat-Sen University; Qilu... and other collaborators

Not yet recruiting

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer (BRIGHT)

Ovarian Cancer

China
Rabin Medical Center

Recruiting

The Effect of Nutritional Formula Supplementation on Linear Growth of Growth Hormone (GH) Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy

ISS- Idiopathic Short Stature

Israel
Juan Du

Recruiting

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Multiple Myeloma

China
University of Minnesota

Recruiting

Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy (LAuGH TRACK)

Growth Hormone Deficiency | Growth Hormone Treatment

United States
University of Colorado, Denver
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse

United States
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Denmark, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Argentina, Sweden, Canada, Spain, Germany, Netherlands, France, Brazil, Greece, Poland, Ireland, Hungary, Portugal, Australia, F... and more
Kinnate Biopharma

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Melanoma | Non-small Cell Lung Cancer | Solid Tumor, Adult

United States, Australia, France, Spain, Taiwan, Korea, Republic of, China, Netherlands
VA Office of Research and Development

Not yet recruiting

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) (GRIT)

Mild Traumatic Brain Injury | Adult Growth Hormone Deficiency

United States
Medical College of Wisconsin

Recruiting

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (IMPEDE)

Multiple Myeloma

United States
Yonsei University
Takeda

Recruiting

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor (NIRVANA-R)

Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Korea, Republic of

3

Subscribe